Spice drugs as a new trend: Mode of action, identification and legislation

Toxicology Letters

Volumn 197, Issue 3, 2010, Pages 157-162

  Vardakou, I ^a   Pistos, C ^a   Spiliopoulou, Ch ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CP 47,497; HU 210; JWH 018; Spice; Synthetic cannabinoids

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3 [2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL]CYCLOHEXANOL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABIDIOL; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOL; CANNABIS; CP 59540; DEXANABINOL; JWH 073; JWH 250; JWH 398; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

AGITATION; CANADA; CANNABIS ADDICTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; EUROPE; HALLUCINATION; HEALTH HAZARD; HUMAN; LAW; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES;

CANNABIS;

EID: 77954954841     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.06.002     Document Type: Review

References (38)

1. Advisory Council on the Misuse of Drugs (ACMD), 2009. Consideration of the major cannabinoid agonists.
2. Aung M.M., Griffin G., Huffman J.W., Wu M.J., Keel C., Yang B., et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding. Drug Alcohol Depend. 2000, 60:133-140.
3. Auwärter V., Dresen S., Weinmann W., Muller M., Putz M., Ferreiros N. Spice and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 2009, 44:832-837.
4. Chin C., Murphy J.W., Huffman J.W., Kendall D.A. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther. 1999, 291:837-844.
5. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 1992, 260:201-209.
6. Compton D.R., Rice K.C., de Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther. 1993, 265:218-226.
7. Dalton V.S., Wang H., Zavitsanou K. HU210-induced downregulation in cannabinoid cb1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem. Res. 2009, 34:1343-1353.
8. EMCDDA-Europol, 2008. Annual Report on the implementation of Council Decision 2005/387/JHA.
9. EMCDDA, 2009a. Early-warning system. Understanding the 'Spice' phenomenon.
10. EMCDDA Poison Control Centre, Mainz, 2009b. Understanding the 'Spice' phenomenon. Via mass media and personal communication.
11. Fergusson D.M., Poulton R., Smith P.F., Boden J.M. Cannabis and psychosis. BMJ 2006, 332:172-175.
12. Geller T. Cannabinoids: a secret history. Chem. Herit. Newsmagazine 2007, 25(2).
13. Glass M., Northup J.K. 'Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1999, 56:1362-1369.
14. Goodman, Gilman's The Pharmacological Basis of Therapeutics 2001, The McGraw-Hill Companies. tenth ed.
15. Griffiths P., Sedefov R., Gallegos A., Lopez D. 'How globalisation and market innovation challenge how we think about and respond to drug use: " Spice" - a case study'. Addiction. 2010, 105:951-953.
16. Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol. Lett. 2004, 25:14-23.
17. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54:161-202.
18. Huffman J.W., Dai D., Martin B.R., Compton D.R. Design, synthesis, and pharmacology of cannabimimetic indoles. Biomed. Chem. 1994, 4:563-566.
19. Intelligence alert " Spice" -Plant materials laced with synthetic cannabinoids or cannabinoid mimicking compounds. Microgr. Bull. 2009, 42:23.
20. Jiang W., Zhang Y., Xiao L., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
21. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., et al. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
22. McLachlan G. Taking the spice out of legal smoking mixtures. Lancet 2009, 374:600.
23. Mechoulam R., Feigenbaum J.J., Lander N., et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988, 44:762-764.
24. Morgan C.J., Curran H.V. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br. J. Psychiatry 2008, 192:306-307.
25. Müller H., Sperling W., Köhrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 2010, 118:309-310.
26. 2α. Eur. J. Pharmacol. 2008, 590:1-11.
27. Ottani A., Giuliani D. HU 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev. 2001, 7:131-145.
28. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005, 7:625-654.
29. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 2006, 147:163-171.
30. Piggee C. Investigating a not-so-natural high. Anal. Chem. 2009, 81:3205-3207.
31. Robinson L., Goonawardena A.V., Pertwee R.G., Hampson R.E., Riedel G. The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats. Br. J. Pharmacol. 2007, 151:688-700.
32. Sobolevsky, T., Prasolov, I., Rodchenkov, G., in press. Detection of JWH-018 metabolites in smoking mixture post-administration urine, Forensic Sci. Int..
33. Sun, Y., Bennett, A., 2007. Cannabinoids: A New Group of Agonists of PPARs. PPAR Research. Article ID. 23513.
34. Teske, J., Weller, J.P., Fieguth, A., Rothämel, T., Schulz, Y., Tröger, H.D., in press. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl) methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B.
35. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol. 2009, 27:61-66.
36. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198:31-38.
37. World Health Organization Expert Committee on Drug Dependence, 2006. 34th report, page 2.
38. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of " Spice Gold" Deutsches Aerzteblatt Intern. 2009, 106:464-467.